for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Business

AstraZeneca shares dip after $39 bln Alexion deal

Posted

AstraZeneca shares fell on Monday, as investors moved to price in the British drugmaker's $39 billion deal for U.S. biotech firm Alexion Pharmaceuticals, the company's largest ever takeover and one of this year's biggest mergers globally. Ciara Lee reports

Business

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up